Drug Trial Radar · NCT07363590
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
21
Planned (sponsor's estimate)
Start
Feb 19, 2026
Primary completion
Jul 16, 2029
Study completion Jul 16, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study looks at a study medicine called MK-1045 in people with lupus and rheumatoid arthritis (RA). The main goal of the study is to learn about the safety of MK-1045 and if people tolerate it when they receive it at different dose levels (amounts).
Conditions
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
Interventions
MK-1045Biological
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants with One or More Adverse Events (AEs)Time frame: Up to approximately 12 weeks
- Part 1: Number of Participants who Discontinue Study Drug Due to an AETime frame: Up to approximately 4 weeks
- Part 2 and Part 3: Number of Participants with One or More AEsTime frame: Up to approximately 52 weeks
- Part 2 and Part 3: Number of Participants who Discontinue Study Drug Due to an AETime frame: Up to approximately 2 weeks
Locations
21 sites in 11 countries. Site status is shown where the registry gives one.
Gold Coast University Hospital ( Site 1601)
Southport, Queensland, Australia · Recruiting
Anima Diepenbeek ( Site 0601)
Diepenbeek, Limburg, Belgium · Recruiting
UZ Gent ( Site 0602)
Ghent, Oost-Vlaanderen, Belgium · Recruiting
Chinese Academy of Medical Science Peking Union Medical College Hospital ( Site 1501)
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Henan University of Science &Technology ( Site 1502)
Luoyang, Henan, China · Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1504)
Wuhan, Hubei, China · Recruiting
Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 1505)
Shanghai, Shanghai Municipality, China · Recruiting
Clinica de la Costa S.A.S. ( Site 0101)
Barranquilla, Atlántico, Colombia · Recruiting
Oncomédica S.A.S ( Site 0103)
Montería, Departamento de Córdoba, Colombia · Recruiting
Fundacion Valle del Lili ( Site 0102)
Cali, Valle del Cauca Department, Colombia · Recruiting
Arensia Exploartory Medicine ( Site 1301)
Tbilisi, Georgia · Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1901)
Roma, Italy · Recruiting
Istituto Clinico Humanitas- IRCCS ( Site 1902)
Rozzano, Milano, Italy · Recruiting
The University of Tokyo Hospital ( Site 0301)
Bunkyo, Tokyo, Japan · Active not recruiting
Keio University Hospital ( Site 0302)
Shinjyuku, Tokyo, Japan · Recruiting
PMSI Republican Clinical Hospital "T.Mosneaga" ( Site 1001)
Chisinau, Moldova · Recruiting
Clinica San Juan Bautista ( Site 0203)
Lima, Peru · Recruiting
ARENSIA Clinics ( Site 0902)
Bucharest, Bucharest, Romania · Recruiting
ARENSIA Exploratory Medicine-Country Emergency Hospital- Arensia,Cluj-Napoca ( Site 0901)
Cluj-Napoca, Cluj, Romania · Recruiting
Chulalongkorn University ( Site 0501)
Pathumwan, Bangkok, Thailand · Recruiting
Ramathibodi Hospital ( Site 0503)
Ratchathewi, Bangkok, Thailand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.